ArticleRheumatology and therapy2020

Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic.

Jennie H Best et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.